Covance And Proliance Collaborate On Drug Development
N/Ampany%> has entered into a strategic alliance with Proliance Pharmaceuticals, Inc., a new company specializing in collaborative drug development. Under the agreement, Covance will be a preferred provider of global services to move Proliance's compounds through development as rapidly and efficiently as possible. In addition, Covance will help the company identify product and partner opportunities.
"Pharmaceutical companies today have a wealth of promising drug candidates in their product pipelines," said Chris Kuebler, chairman and CEO, Covance, Inc. "Through our relationship with Proliance, Covance hopes to further leverage its world-class development capabilities and help the industry to better optimize the value of their discovery efforts."
For more information: Beth Leahy, Covance, Inc., 210 Carnegie Center, Princeton, NJ 08540-6233. Telephone: 609-452-4978. Fax: 609-452-9375.